Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis

被引:36
|
作者
Tiao, Darren K. [1 ,2 ]
Chan, Webber [1 ]
Jeganathan, Jayson [1 ,2 ]
Chan, Jenny T. [1 ]
Perry, Jonathan [1 ,2 ]
Selinger, Christian P. [1 ]
Leong, Rupert W. [1 ,2 ,3 ]
机构
[1] Concord Hosp, Gastroenterol & Liver Serv, Sydney, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] UNSW, South Western Sydney Clin Sch, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
inflammatory bowel disease; adherence; medication; counseling; colitis; Crohn's disease; treatment; MAINTENANCE MEDICATION; NONADHERENCE;
D O I
10.1097/MIB.0000000000001194
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: While inflammatory bowel diseases (IBD) require long-term medication usage to maintain remission, nonadherence is common and adversely associated with poorer clinical outcomes. Personalized IBD Pharmacist Adherence Counselling, based on the Health Beliefs Model of medication perception, may increase medication adherence. Methods: This prospective multi-center longitudinal parallel study recruited consecutive IBD subjects that were classified as baseline medication non-adherers and adherers. Non-adherers received a single IBD Pharmacist Adherence Counselling intervention at baseline, while adherers served as controls. Medication Adherence Report Scale and Beliefs about Medicines Questionnaire were administered up to 24 months. Medication acceptance was defined as high perception of medication necessity with low concerns. The primary endpoint was medication adherence at 24 months. Results: Of 114 subjects approached, 100 completed follow-up, with 36 being baseline nonadherers (median Medication Adherence Report Scale = 15.0) and 64 baseline adherers (median Medication Adherence Report Scale = 19.0; P, 0.001). At 24 months, nonadherence in the IBD Pharmacist Adherence Counselling group decreased from 100% to 44.4% (P = 0.001), whereas nonadherence in controls remained unchanged (P = 0.38). Individually, Beliefs about Medicines Questionnaire Necessity and Concern scores showed no significant changes in both groups, but medication acceptance significantly improved in baseline nonadherers at 12 months (P = 0.031) with a trend toward durable improvement at 24 months (P = 0.063). Conclusions: Medication nonadherence in IBD can be improved through a single personalized counseling session by an IBD pharmacist, and the benefit was durable for 2 years. This benefit was through improving the acceptance of medication.
引用
收藏
页码:257 / 261
页数:5
相关论文
共 50 条
  • [21] Validation of the Spanish version of the Inflammatory Bowel Disease Questionnaire on ulcerative colitis and Crohn's disease
    Lóopez-Vivancos, J
    Casellas, F
    Badia, X
    Vilaseca, J
    Malagelada, JR
    DIGESTION, 1999, 60 (03) : 274 - 280
  • [22] PPARγ and inflammatory bowel disease:: a new therapeutic target for ulcerative colitis and Crohn's disease
    Wada, K
    Nakajima, A
    Blumberg, RS
    TRENDS IN MOLECULAR MEDICINE, 2001, 7 (08) : 329 - 331
  • [23] Extraintestinal manifestations in inflammatory bowel disease:: differences between Crohn's disease and ulcerative colitis
    Mendoza, JL
    Lana, R
    Taxonera, C
    Alba, C
    Izquierdo, S
    Díaz-Rubio, M
    MEDICINA CLINICA, 2005, 125 (08): : 297 - 300
  • [24] Inflammatory bowel disease (ulcerative colitis and Crohn's disease): Diagnostic criteria and differential diagnosis
    Winther, KV
    Fogh, P
    Thomsen, OS
    Brynskov, J
    DRUGS OF TODAY, 1998, 34 (11) : 935 - 942
  • [25] Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease
    Fan, Fenling
    Mundra, Piyushkumar A.
    Fang, Lu
    Galvin, Abby
    Moore, Xiao Lei
    Weir, Jacquelyn M.
    Wong, Gerard
    White, David A.
    Chin-Dusting, Jaye
    Sparrow, Miles P.
    Meikle, Peter J.
    Dart, Anthony M.
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) : 1511 - 1518
  • [26] Cutaneous involvement in chronic inflammatory bowel disease. Crohn's disease and ulcerative colitis
    Richter, L.
    Rappersberger, K.
    HAUTARZT, 2016, 67 (12): : 940 - 947
  • [27] Osteoporosis and inflammatory bowel disease in children: Differences between Crohn's disease and ulcerative colitis
    Paganelli, M
    Civitelli, F
    Albanese, C
    Lucarelli, S
    Borrelli, O
    Cirulli, M
    Cordischi, L
    Cucchiara, S
    BONE, 2005, 36 : S76 - S77
  • [28] Colonic inflammatory bowel disease - Medical therapie's for colonic Crohn's disease and ulcerative colitis
    Tung, JK
    Warner, AS
    POSTGRADUATE MEDICINE, 2002, 112 (05) : 45 - +
  • [29] Clinicians' adherence to European Crohn's and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel disease
    Jackson, B.
    Con, D.
    De Cruz, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S348 - S349
  • [30] Identifying Targets for Improving Inflammatory Bowel Disease Medication Adherence
    Sheehan, Jessica
    Berinstein, Jeff
    Swanson, Linnea
    Greene-Higgs, LaVana
    Waljee, Akbar
    Higgins, Peter
    Cohen-Mekelburg, Shirley
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S372 - S373